Onglyza Lawyers Appointed to Leadership Roles in Federal MDL Over Heart Failure Risk

With more than two hundred Onglyza lawsuits pending in the federal court system, each involving similar allegations that the diabetes drug caused users to develop heart failure, the U.S. District Judge presiding over the litigation has appointed a small group of plaintiffs’ attorneys to serve in various leadership roles in the recently established multidistrict litigation (MDL).

Onglyza (saxagliptin) was introduced for treatment of type 2 diabetes in 2009, but heart safety concerns have emerged in recent years, leading the FDA to require stronger label warnings about the risk of congestive heart failure and other cardiovascular complications.

As a result, a growing number of product liability complaints have been filed by individuals nationwide, presenting similar claims that AstraZeneca knew or should have known about the Onglyza heart failure risks for years, yet failed to adequately warn users and the medical community.

Learn More About

Onglyza Lawsuits

Given similar questions of fact and law presented in the cases, U.S. District Judge Karen Caldwell has been appointed to preside over the consolidated pretrial proceedings and coordinated discovery in the Eastern District of Kentucky.

In an order (PDF) issued on September 6, Judge Caldwell appointed different plaintiffs’ attorneys to serve 16 different leadership roles in the litigation. These attorneys will take certain actions during the MDL proceedings that will benefit all plaintiffs who are pursuing cases.

The appointments include two Onglyza lawyers who will serve as Plaintiffs’ Co-Lead Counsel, one as Plaintiffs’ Liaison Counsel, a three-member Plaintiffs’ Executive Committee, a Plaintiffs’ Federal-State Court Liaison Counsel, and a nine-member Plaintiffs’ Steering Committee.

The establishment of a leadership group for plaintiffs counsel is common in complex medical device litigation, where a large group of cases present similar claims. The lawyers will conduct general discovery into common issues, argue motions before the court and coordinate with individual attorneys with cases in the MDL. However, each plaintiff will still maintain their own lawyer, who will be responsible for case-specific deadlines and establishing causation between that plaintiffs use of Ongylza and heart failure injury.

As part of the coordinated pretrial proceedings, it is expected that Judge Caldwell will establish a bellwether process, where a small group of cases will be scheduled for early trial dates to help gauge how juries may respond to certain evidence and testimony that is likely to be repeated throughout the litigation

If Onglyza heart failure settlements are not reached following the coordinated MDL proceedings, each case may ultimately be remanded back to the U.S. District Court where it was originally filed for an individual trial date in the future.

Judge Caldwell issued a preliminary scheduling order (PDF) on September 7, giving the plaintiffs’ co-lead counsel 14 days to submit a brief regarding a request by the defense to bifurcate the pretrial proceedings into two phases, with the first phase dedicated to general causation. The next conference is scheduled for December 18, 2019.

0 Comments

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Uber Driver Sexual Assaults and Misconduct Reports Must Be Disclosed in Lawsuit Discovery
Uber Driver Sexual Assaults and Misconduct Reports Must Be Disclosed in Lawsuit Discovery (Posted today)

A federal magistrate judge is forcing Uber to hand over potentially hundreds of thousands of incident files involving reports of passengers who suffered sexual misconduct or sexual assault at the hands of the rideshare service's drivers.

Abbott May Remove Infant Formula for Preemies Off the Market Due to Similac NEC Lawsuits
Abbott May Remove Infant Formula for Preemies Off the Market Due to Similac NEC Lawsuits (Posted yesterday)

Abbott Laboratories is considering removing Similac infant formula products designed for preterm babies from the market, as it faces hundreds of lawsuits claiming the products increase the risk of necrotizing enterocolitis, which puts newborns at a high risk of permanent injuries and death.

Information About Suboxone Dental Claims To Be Exchanged By Parties in MDL
Information About Suboxone Dental Claims To Be Exchanged By Parties in MDL (Posted 2 days ago)

A federal judge has ordered parties involved in Suboxone dental decay lawsuits to submit proposals for exchanging information that will guide the selection of representative bellwether claims for early test trials.